INTRODUCTION {#s1}
============

Death due to breast cancer results largely from metastatic spread of the disease \[[@R1], [@R2]\]. This process encourages cells to break apart from the tumor and travel through the body to another organ \[[@R2], [@R3]\]. It has become increasingly clear that metastatic progression correlates with the deregulation of certain gene sets in the primary tumor \[[@R4], [@R5]\]. Therefore, the identification of key molecules that control metastatic signaling cascades holds the best opportunity to design new therapeutic strategies for advanced breast cancer.

The human *ADP-ribosylation factor (ARF)* gene family has 5 members (*ARF1*, *ARF3*, *ARF4/ARF2*, *ARF5* and *ARF6*), which encode 5 ARF proteins categorized as class I (ARF1 and ARF3), class II (ARF4 and ARF5) and class III (ARF6) \[[@R6]--[@R8]\]. Like the Ras superfamily of proteins, ARFs are small GTPases and their functions are highly regulated by switching between active GTP- bound and inactive GDP-bound conformations \[[@R9], [@R10]\]. ARF1 and ARF6 are well characterized as crucial regulators for vesicular trafficking, and their roles have been implicated in the cancer progression. ARF6 is often overexpressed in many types of cancer and facilitates epithelial-mesenchymal transition and invasiveness \[[@R11], [@R12]\]. ARF6 anchors to the plasma membrane, where it recruits ARNO and coordinates membrane trafficking and cytoskeleton remodeling \[[@R13]\]. Unlike ARF6, ARF1 especially regulates translocation of proteins from trans-Golgi network to plasma membrane, and directly activates signaling molecules \[[@R7], [@R14]--[@R16]\].

In prostate cancer, we have linked ARF1 to the hyperactivation of mitogen activated protein kinase (MAPK) Raf1/MEK/ERK1/2 pathway \[[@R7]\]. In breast cancer, ARF1 has been reported to be involved in promoting cell proliferation and migration via multiple well-known signaling cascades. For example, ARF1 controls cell adhesion by regulating the recruitment of key focal adhesion proteins (such as paxillin, talin and FAK) to β1-integrin \[[@R17]\], controls cell proliferation by regulating pRB/E2F1 activity and gene expression \[[@R15]\], and controls cell migration and invasion by regulating the activation of Rac1 and PI3K/AKT pathways \[[@R14], [@R16]\]. Most recently, ARF1 is shown to act as a molecular switch to activate EGF-mediated responses and mediate the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors \[[@R18]\]. On the basis of these clues, we wondered whether ARF1 functions as a metastasis promoter in breast cancer to drive metastasis. Here we provide evidence for such a role, and demonstrate that ARF1 is a very compelling target to limit breast cancer metastasis. Inactivating ARF1 may have a potential therapeutic value in this regard.

RESULTS {#s2}
=======

High-level amplification of *ARF1* gene in breast cancer {#s2_1}
--------------------------------------------------------

To explore whether the *ARF* genes contribute to the occurrence and development of cancer, we investigated the genetic alteration of a panel of the *ARF* gene family using publicly accessible TCGA datasets (see Materials and methods). Intriguingly, amplification of the *ARF genes* was found in 17% of cases of breast cancer, which was the highest in all the examined cancer types (Figure [1A](#F1){ref-type="fig"}). Amplification was the predominant type of alteration for *ARF1* gene and its frequency was much higher (14% of cases) than other family members in breast cancer. Functional plotting of the corresponding mRNA level in relation to genetic status of *ARF1* revealed that amplification of *ARF1* was associated with increased mRNA expression (Figure [1B](#F1){ref-type="fig"}). To further validate these findings, the relative expression of the *ARF1* transcript was examined in breast cancer entities from the Oncomine database, which showed *ARF1* expression levels were significantly higher in cancer than normal tissues (Figure [1C](#F1){ref-type="fig"}). Univariate survival analysis (Kaplan-Meier method and log-rank test) revealed that breast cancer patients with low levels of *ARF1* expression significantly improved relapse-free survival as compared with high expression levels (Figure [1D](#F1){ref-type="fig"}), which is likely to be related to its involvement in the lethal and advanced forms of breast cancer.

![High-level amplification of *ARF1* is associated with increased mRNA expression and poor outcomes of patients with breast cancer\
(**A**) Summary graph of genetic alterations of the *ARF* genes in individual studies deposited in the cBioPortal. The amplification frequency of *ARFs* in breast cancer is shown in the inset. (**B**) A plot of the correlation between copy number alterations and mRNA expression of the *ARF1* gene. (**C**) Analysis of *ARF1* expression in breast normal and cancer tissues using Oncomine database. (**D**) Kaplan-Meier plot of RFS shown for breast cancer patients with high (red) and low (black) expression levels of the *ARF1* gene.](oncotarget-07-58111-g001){#F1}

ARF1 is upregulated in human breast cancer tissues {#s2_2}
--------------------------------------------------

To validate the ARF1 expression pattern at protein levels, breast cancer tissue microarrays were used for immunohistochemistry (IHC) analysis. Our data indicate remarkably increased levels of ARF1 in primary breast cancer tissues compared with normal breast epithelium, and strong membrane staining of ARF1 in advanced breast cancer (Figure [2A](#F2){ref-type="fig"}). Most interestingly, higher levels of ARF1 were associated with higher cancer stages (Figure [2](#F2){ref-type="fig"}), supporting its critical role in breast cancer progression.

![ARF1 is upregulated in human breast cancer tissues\
(**A**) Representative IHC results for ARF1 expression in breast cancer tissue arrays. (**B**) Quantitative data of staining intensity presented as integrated optical density (IDO). \*\**p* \< 0.01; \*\*\**p* \< 0.001.](oncotarget-07-58111-g002){#F2}

Loss of *ARF1* expression suppresses metastasis in breast cancer {#s2_3}
----------------------------------------------------------------

To better understand the role of ARF1 in breast cancer, we used shRNA constructs to inhibit *ARF1* expression in high-invasive breast cancer MDA-MB-231 cells (Figure [3A](#F3){ref-type="fig"}). Using two different shRNA constructs, knockdown of *ARF1* led to significantly reduced potential in cell invasion within 24 hours (Figure [3B](#F3){ref-type="fig"}) with modest decreased cell proliferation. To explore the importance of *ARF1* in metastasis *in vivo*, MDA- MB- 231 cells with *ARF1* knockdown were injected into the mammary fat pad of NSG mice and metastasis was monitored in these orthotopic breast cancer models. When pulmonary metastasis was examined at the conclusion of the experiment, mice injected with the knockdown control cells showed more nodules on the lung surface with heavier weights (Figure [3C](#F3){ref-type="fig"} and [3D](#F3){ref-type="fig"}), compared with those injected with *ARF1* knockdown cells. Histological analysis of these lungs further revealed a notable decrease in the number and size of metastatic foci on lung section when *ARF1* was depleted (Figure [3E](#F3){ref-type="fig"}).

![Knockdown of ARF1 leads to reduced cell invasion and metastasis in breast cancer\
(**A**) The effect of shRNA-mediated *ARF1* knockdown on MDA-MB-231 cells. (**B**) The effect of *ARF1* depletion on cell invasion. (**C, D, E, F**) The effect of *ARF1* depletion by shRNA on pulmonary metastases in the orthotopic mice model of breast cancer. (C, D) Quantitative data of lung weigh and gross surface pulmonary metastases. (E) Representative H&E stained lung sections from tumor-bearing mice. Six weeks after injection with MDA-MB-231 cells, the lungs from the NSG mice sacrificed were excised for pathological and histological analysis. Black arrows indicate representative metastatic foci. (F) The effect of *ARF1* depletion by shRNA on metastatic dissemination in zebrafish. White arrows indicate disseminated MDA-MB-231 cells in the fish body. Quantitative data are shown in right panel. \*\**p* \< 0.01.](oncotarget-07-58111-g003){#F3}

Owing to the transparent and immunoprivileged nature of zebrafish embryos, we have recently established a zebrafish-metastasis model through a critical evaluation of various types of human cancer cells \[[@R19]--[@R21]\]. To determine whether the phenotype results from *ARF1* knockdown is reproducible in the zebrafish-metastasis model, we generated tumor-bearing zebrafish through injecting *ARF1* knockdown MDA-MB-231 cells and the knockdown control cells. Consistent with the findings from NSG mice, metastatic dissemination of the knockdown control cells was seen in 76% zebrafish at 2 days post-injection (dpi), whereas *ARF1* knockdown cells were only disseminated in 24% of zebrafish (Figure [3F](#F3){ref-type="fig"}). These observations demonstrate that *ARF1* is required for breast cancer progression and acts as a metastasis promoter.

LM11 inhibits ARF1 activation in breast cancer cells in a dose-dependent manner {#s2_4}
-------------------------------------------------------------------------------

We next determined levels of ARF1 expression and activation status in well-established human breast cancer cell lines. Real-time RT-PCR revealed elevated expression levels of *ARF1* in cancer cells (MCF7, MDA-MB-231 and Hs578T) when compared to human MCF10A mammary epithelial cells (Figure [4A](#F4){ref-type="fig"}). Moreover, the expression levels of ARF1 in two triple-negative cell lines (MDA-MB-231 and Hs578T) were much higher than those in MCF7 cells (Figure [4A](#F4){ref-type="fig"}). Interestingly, the levels of active GTP-bound ARF1 were strongly correlated with ARF1 expression in breast cancer cells (Figure [4B](#F4){ref-type="fig"}).

![LM11 inhibits ARF1 activation in breast cancer cells\
(**A**) The relative expression levels of *ARF1* in breast normal and cancer cells. (**B**) The activation of ARF1 in breast normal and cancer cells. (**C**) The effect of LM11 on the activation of ARF1 in breast cancer. Quantitative data of relative ARF1 activation (LM11 *vs* DMSO) are shown in right panel.](oncotarget-07-58111-g004){#F4}

The data shown above suggest that inhibiting ARF1 expression may be a means of suppressing aggressive stage of breast cancer. However, there are no drugs directly targeting ARF1 expression. ARF1 is a small GTPase and its function largely dependents on the active form \[[@R7], [@R9], [@R10]\], therefore, we investigated the efficacy of the inhibitors blocking ARF1 activation. We have previously reported that a small molecule LM11 can effectively impair ARF1 activation in HeLa cells through targeting ARF1-GDP and ARF nucleotide-binding site opener (ARNO) in regions close to the ARF1/ARNO interface \[[@R22], [@R23]\]. As shown in Figure [4C](#F4){ref-type="fig"}, LM11 also inhibited ARF1 activation in breast cancer cells, and this effect was dose dependent.

LM11 inhibits cell viability and invasion in breast cancer cells {#s2_5}
----------------------------------------------------------------

To specifically evaluate the effect of LM11 on breast cancer, we determined the *in vitro* cytotoxicity of LM11 in three breast cancer cell lines. Cell viability assays using CellTiter-Glo^®^ Luminescent cell viability kit (Promega, Madison, MI) showed that the IC~50~ (50% inhibitory concentration) of LM11 in the examined breast cancer cell lines ranged from 40 μM (MDA-MB-231 and Hs578T) to 75 μM (MCF7) (Figure [5A](#F5){ref-type="fig"}). Flow cytometry-based analysis further indicated, unlike high dose (50 μM), low dose of LM11 (10 μM) only modestly affected cell viability of breast cancer cells (Figure [5B](#F5){ref-type="fig"}). We thus determined LM11 effect on cell motility at low dose. Gap closure migration assays showed that LM11 significantly inhibited cell migration in both MDA-MB-231 and Hs578T cells (Figure [5C](#F5){ref-type="fig"} and [5D](#F5){ref-type="fig"}). Moreover, transwell invasion assays demonstrated that LM11 treatment led to a sharp decreased in invasion potential in these cells (Figure [5C](#F5){ref-type="fig"} and [5E](#F5){ref-type="fig"}). These data indicate that LM11 exhibits potent *in vitro* cytotoxicity and suppression of invasion in breast cancer cells.

![LM11 exhibits potent *in vitro* cytotoxicity and inhibits migration and invasion of breast cancer cells\
(**A, B**) The effect of LM11 on cell viability in breast cancer cells. MCF7, MDA-MB-231 and Hs578T breast cancer cell lines were treated with different doses of LM11 (10--100 μM) for 24 hours and cell viability was determined by CellTiter-Glo^®^ Luminescent cell viability kit (A). LM11-treated MDA-MB-231 and Hs578T cells were stained with Zombie Aqua^TM^ dye and cell viability was determined by flow cytometry (B). (**C, D, E**) The effect of LM11 on cell migration and invasion in breast cancer cells. Representative images of these assays shown in (C) and quantitative data shown in (D) and (E). MDA-MB-231 and Hs578T cells were treated with LM11 for 24 hours and cell migration and invasion were determined by Gap closure and Boyden chamber, respectively. \**p* \< 0.05; \*\**p* \< 0.01.](oncotarget-07-58111-g005){#F5}

LM11 effectively suppresses breast cancer metastasis {#s2_6}
----------------------------------------------------

The zebrafish-metastasis model can evaluate the metastatic ability of cancer cells \[[@R19]--[@R21], [@R24]\]. We have shown above (Figure [3](#F3){ref-type="fig"}) that zebrafish robustly reported the decreased metastasis potential in breast cancer cells where the *ARF1* gene was knocked down. Therefore, we used this model to evaluate the efficacy of LM11 in suppression of breast cancer metastasis. To ensure that the effect was specific to tumors and did not affect the zebrafish development and growth, the overall length of each fish was recorded under bright field illumination before and after LM11 treatment. At the concentration ranging from 0.1--1 μM, LM11 did not alter overall fish growth within 1 week of treatment, as compared with the treatment of vehicle (DMSO) (data not shown). Most importantly, 1 μM of LM11 significantly inhibited MDA-MB-231 cells to disseminate from the perivitelline cavity to fish body (Figure [6](#F6){ref-type="fig"}). These observations demonstrate that LM11 has strong anti-cancer activities through suppressing the phenotypes associated with breast cancer metastasis.

![LM11 effectively suppresses breast cancer metastasis in the zebrafish model\
Tumor-bearing zebrafish were treated with 1 μM of LM11 for 4 days, and LM11 efficacy in metastatic dissemination was determined by confocal microscopy. White arrows indicate disseminated MDA-MB-231 cells in the fish body. Quantitative data are shown in right panel. \*\**p* \< 0.01.](oncotarget-07-58111-g006){#F6}

DISCUSSION {#s3}
==========

ARFs are a family of GTPases involved in a range of cellular functions, including critical functions in vesicular transport \[[@R25]\]. Here we show that ARF1 is often abnormally overexpressed in breast cancer cells, and such overexpression is crucial to promote invasion and metastasis to be significantly associated with the poor outcomes of patients. Based on these facts, we demonstrate that ARF1 serves as a previously unidentified drug target and inactivating it can suppress metastatic breast cancer. The study of breast cancer metastasis is always hampered by a lack of reliable metastatic models. Although the importance of the *ARF1* gene has been determined using tail vein injection of immunocompromised SCID mice \[[@R26]\], intravascular injections only model extravasation and metastasis, and lack the growth characteristics and metastatic properties of human cancer \[[@R27]\]. Considering that NSG mice allow primary and metastatic tumors to develop coincidently \[[@R28]\], we established orthotopic breast cancer models in NSG mice to illustrate the contribution of *ARF1* alteration to cancer progression. Orthotopic implantation in mice indicates that loss of *ARF1* expression in breast cancer cells reduces risk of metastatic spread. These findings, together with the investigation in zebrafish, provide more solid evidence that ARF1 promotes breast cancer metastasis.

Mutations in *RAS* genes are very rare in human breast cancers, but RAS is pathologically hyperactivated in half of these cancers \[[@R29]--[@R31]\]. Since approaches to directly target RAS have not been successful, most efforts to block activated RAS have focused on pathways downstream, such as the MAPK and PI3K pathway \[[@R32], [@R33]\]. However, targeting these nodes in the signaling cascades individually typically involves a switch to the other pathway in a rescue strategy by the cancer cells to overcome monotherapies \[[@R34]--[@R37]\]. Previous studies demonstrate, similar to the oncogene RAS, ARF1 directly and activation-dependently activates the MAPK and PI3K pathway \[[@R7], [@R14], [@R26]\]. Therefore, inhibition of ARF1 may provide an alternative over the generally toxic simultaneous inhibition of multiple pathways by different drugs.

The exchange of GDP for GTP on ARFs is catalyzed by guanine nucleotide exchange factors (GEFs), and ARF- GEFs interact with ARFs through their Sec7 domain, which is necessary and sufficient for GEF activity \[[@R38]--[@R40]\]. Most existing ARF1 inhibitors block its activation by targeting the Sec7 domain on ARF1-GEFs \[[@R22]\]. Although inactivating a subset of ARF1-GEFs has been very useful for assessing the ARF1 function, ARF1 inhibitors remain a daunting challenge to develop into anti-cancer and anti-inflammatory drugs. For example, Brefeldin A (BFA), a known inhibitor stabilizing an abortive complex between the GEFs and ARF1 in the GDP-bound form, is highly cytotoxic \[[@R40]\]. Unlike BFA, Exo2 interferes with the function of ARF1 or ARF1-GEFs localized to the ER-Golgi intermediate compartment or the *trans-*Golgi network. While compared to BFA, Exo2 reduces ARF1 activation but the effect is much weaker \[[@R41]\]. Recently, a novel ARF1- ARFGEF inhibitor AMF-26, which differed structurally from BFA, has shown potential for inducing complete regression of human breast cancer BSY-1 xenografts *in vivo* \[[@R42]\]. However, no evidence has been provided that AMF26 and its derivatives has anti-metastasis effects. We have characterized a compound, LM11, specifically targets the ARF1-GDP/cytohesin-2 complex and acts as a non-competitive inhibitor \[[@R22]\]. In MDCK cells, LM11 suppresses ARNO-dependent migration because of its inhibition of ARF1 functions at the Golgi \[[@R22]\]. The data present here, for the first time, show potential therapeutic opportunities for breast cancer resulting from ARF1 inactivation in the context of LM11 treatment.

Recently, more general cancer characteristics such as genomic instability, invasiveness, and transplant ability apply to zebrafish tumors \[[@R19]--[@R21], [@R24], [@R43], [@R44]\]. As a model of whole organism, zebrafish can be used to facilitate better understanding of gene function involved in cancer progression and provide a means to develop promising preclinical agents. We evaluated ARF1 function and LM11 efficacy using the zebrafish-metastasis model. The value of fish assays is that the results can be obtained in an informative, cost-effective and time-efficient manner. The mice, therefore, will be used to confirm the effect of LM11 on suppression of metastasis.

MATERIALS AND METHODS {#s4}
=====================

Cell lines and standard assays {#s4_1}
------------------------------

Human breast cancer cell lines (MDA-MB-231, Hs578T and MCF7) and normal mammary epithelial cells MCF10A were directly obtained from American Type Culture Collection (ATCC, Rockville, MD). All the cell lines used in this study have been verified using SNP-CGH for characteristic cytogenetic changes or confirmed using STR DNA fingerprinting analysis \[[@R45], [@R46]\]. Standard cell culture, transient transfections, lentiviral transduction, western blot, real-time RT-PCR and cell proliferation assays were carried out as described previously \[[@R28], [@R45]--[@R47]\].

Constructs, antibodies and other reagents {#s4_2}
-----------------------------------------

To stably knock down the *ARF1* gene, pLKO.1 lentiviral vectors harboring shRNA-targeting *ARF1* were obtained from Open Biosystems (Huntsville, AL). ARF1 and β-Actin antibodies were procured from Abcam (Cambridge, MA) and Sigma (St Louis, MO), respectively. The ARF1 inhibitor LM11 was obtained from ChemBridge (San Diego, CA). ARF1 activation was determined by the glutathione resin-bound GST-GGA3-PBD fusion protein as described previously \[[@R8]\].

Cell viability and flow cytometric analysis {#s4_3}
-------------------------------------------

The cell viability was determined by CellTiter-Glo^®^ Luminescent cell viability assay (Promega, Madison, MI) and Zombie Aqua^TM^ fixable viability kit (BioLegend, San Diego, CA) according to manufacturer\'s instructions. Flow cytometry (LSR Fortessa cell analyzer, BD Biosciences, San Jose, CA) was used to record and analyze the cells stained with Zombie Aqua^TM^ dye with a maximum emission of 516 nm.

Gap closure migration assays and invasion assays {#s4_4}
------------------------------------------------

Cell migration was performed using the Radius™ 24-well from Cell Biolabs (San Diego, CA). Briefly, cells were seeded on Radius cell migration plates and allowed to form monolayers. Circular gaps were generated by removing the gels and cells were treated with DMSO or LM11 for 24 hours. To compare differences in the migratory gap, phase-contrast images were captured at the same size using a Zeiss LSM-510 inverted microscope (Zeiss, Germany) and gap closure was analyzed using ImageJ. Cell migration velocity was calculated and statistically analyzed from three independent experiments. Cell invasion was performed using a Matrigel-coated modified Boyden chamber (BD biosciences, San Jose, CA) as described previously \[[@R45]--[@R47]\]. After incubation for 24 hours, cells on the upside were removed using cotton swabs, and the invading cells on the lower side were fixed and stained with 0.2% crystal violet. Numbers of the invading cells in six randomly selected fields were counted in each experiment using a Zeiss LSM-510 inverted microscope.

Experimental metastasis assays {#s4_5}
------------------------------

All experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at Augusta University. Tg(*kdrl:*EGFP) transgenic zebrafish which highlights the vasculature were maintained using established temperature and light cycle conditions as previously described \[[@R19], [@R48], [@R49]\]. In zebrafish metastasis assays, cancer cell transplantation was performed essentially as described previously \[[@R19]\]. Briefly, MDA-MB-231 cells infected with the lentivirus expressing control or *ARF1* shRNA were labeled with fluorescent dye CM-Dil (Life Technologies, Carlsbad, CA). Approximately 200 labeled MDA-MB-231 cells expressing *ARF1* shRNA or control shRNA were microinjected into the perivitelline space of 2 days post fertilization (dpf) Tg(*kdrl:*EGFP) embryos. The embryos were kept at 34°C and then imaged under anesthesia by confocal microscopy at 2 dpi. Percentage of metastasis was set as the number of embryos containing more than 5 cells outside the yolk sac. Total metastasis percentage was set as the total number of embryos with metastasis at 2 dpi relative to day zero. In mouse metastasis assays, *ARF1* knockdown MDA-MB-231 cells and the control cells were individually injected into 6-week-old female NSG mice (NOD.Cg- *Prkdc*^scid^*Il2rg*^tm1Wjl^/SzJ, Jackson Laboratory, Bar Harbor, ME) through the mammary fat pad under the fourth (abdominal) nipple as described previously \[[@R28]\]. Mice were sacrificed 6 weeks after injection and the lungs were then fixed in 10% neutral buffered formalin, embedded in paraffin blocks, sectioned at 5 μm, and subjected hematoxylin and eosin (H&E) staining.

Zebrafish drug treatment {#s4_6}
------------------------

Tg(*kdrl:*EGFP) embryos at 2 dpf were injected with MDA-MB-231 cells and housed in 24-well plates containing a single larva per well in 500 μl filter-sterilized fish water. Fish were administrated with 0.5% DMSO or different doses of LM11 in the fish water at 4 hours post-injection (hpi). After 4 days of treatment, metastasis in fish body was analyzed using confocal microscopy. Percentage of metastasis was set as the number of embryos containing more than 5 cells outside the yolk sac. Total metastasis percentage was set as the total number of embryos with metastasis at 4 dpi relative to day zero.

Tissue microarrays and IHC {#s4_7}
--------------------------

The human breast tissue microarrays were purchased from US Biomax (Rockville, MD) and Novus Bio (Littleton, CO). IHC of the human tissue microarrays was conducted as described previously \[[@R7]\] using an ARF1 antibody (1:500). For quantifying staining intensity, 12 random microscopic fields were captured by a CCD camera (Olympus, Center Valley, PA) and signal intensity was determined using the Image-Pro Plus software (MediaCybernetics, Rockville, MD).

Bioinformatics and statistical analysis {#s4_8}
---------------------------------------

To determine the influence of *ARF1* expression on relapse-free survival of breast cancer patients, integrated available genome-level transcriptomic datasets from the Kaplan Meier (KM)-plotter \[[@R50]\] were assessed by stratifying patients based on the higher or lower *ARF1* expression. The genetic status of human *ARF* gene family related to cancer types was calculated from TCGA data by cBioPortal (<http://www.cbioportal.org/>) up to April 2016. The selected datasets in this study must contain a large number of patient samples (\> 100). Expression data of *ARF1* in normal breast and breast cancer samples were obtained from Oncomine website ([www.oncomine.org](http://www.oncomine.org/)). Experiments shown are the means of multiple individual points from multiple experiments (± S.D.). A 2-tailed *P*-value of less than 0.05 was considered to indicate statistical significance.
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